The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Mitral Regurgitation
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Cephea Early Feasibility Study
-
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
University of California - Davis Medical Center, Sacramento, California, United States, 95817
Piedmont Heart Institute, Atlanta, Georgia, United States, 30309
Cardiovascular Research Institute of Kansas, Wichita, Kansas, United States, 67226
University of Michigan, Ann Arbor, Michigan, United States, 48109
Minneapolis Heart Institute, Minneapolis, Minnesota, United States, 55407
Montefiore Medical Center, Bronx, New York, United States, 10467
Carolinas Medical Center, Charlotte, North Carolina, United States, 28203
The Cleveland Clinic Foundation, Cleveland, Ohio, United States, 44195
St. Thomas Hospital, Nashville, Tennessee, United States, 37205
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Abbott Medical Devices,
Barathi Sethuraman, STUDY_DIRECTOR, Abbott Structural Heart
2031-03-01